Butterfly Network, Inc. Q3 2026 Earnings Call - BUTTERFLY NETWORK INC

Explicit Guidance:

• Full Year 2026 Revenue: Increased guidance range to $123–126 million (up $4M at the bottom and $3M at the top from prior guidance), implying Q4 2026 revenue of $31–34 million. This represents a 26–29% year-over-year increase over 2025.
• Full Year 2026 Adjusted EBITDA: Increased guidance range to a loss of $12–15 million (up $8M at the bottom and $7M at the top from prior guidance), implying a Q4 2026 adjusted EBITDA loss of $3–6 million.
• Long-Term Profitability: Management targets being adjusted EBITDA and cash flow positive by 2028 with current capital.
• Embedded Revenue Run Rate: Expects to maintain a run rate of approximately $7–8 million per quarter into 2027, though actuals are currently trending above historical guidance due to new partnerships.
• Capital Structure: Established an At-The-Market (ATM) equity program for up to $150 million over the next three years; no immediate need for cash and issuance is purely opportunistic.

Business-Segment Outlook:

• Core POCUS (U.S. Enterprise): Pipeline converted successfully with 5 seven-figure TCV deals and 10 six-figure TCV deals closed in Q3 2026; expecting acceleration in 2027.
• Federal Government: FedRAMP authorization achieved in Q3; organic pipeline building with proactive inclusion in RFIs for large-scale government efforts.
• International POCUS: Shifting strategy from individual clinicians to larger institutional/enterprise customers to mirror U.S. success; expects improved performance in Q4 2026 and into 2027; new distributor in Taiwan and traction in Brazil.
• Embedded: Revenue expected to grow consistently into 2027 driven by existing partners (MidJourney, Merge Labs, Bridge Neurotech) and a growing pipeline; long-term potential of $550 million revenue by 2030 if MidJourney's trajectory holds (representing only a fraction of total embedded potential).
• Home and Community Care: Scanning began in November 2026; initial revenue expected in Q4 2026; expansion to other markets anticipated through 2027; revenue could become meaningful in 2028.
• Product Lifecycle: Launching next-generation P5.1 chip (tissue harmonics) in early 2027 to set new image quality standards; entry into the $8 billion cart-based ultrasound market expected in 2028.

Market and Competitive Outlook:

• Competitive Landscape: Anticipates smaller competitors struggling to find footing and larger incumbents (e.g., Philips, GE) pulling back from underinvested general ultrasound markets; Butterfly is "leaning in" with semiconductor-based differentiation.
• Market Share: Butterfly holds more than double the market share of any international region in the U.S.; international market share expected to grow as the U.S. playbook is implemented globally.
• Demand Trends: Health systems increasingly recognizing the necessity of Compass AI for data management and compliance; growing interest in physical AI and wearable form factors for continuous monitoring.

Macro / Industry Outlook:

• Geopolitics & Supply Chain: Monitoring conflicts in the Middle East, global tariff pressures, and AI-driven supply chain shortages; these impacts are currently managed and minor, fully reflected in current guidance.
• Regulatory: FedRAMP achievement opens access to the federal government, the world's largest healthcare purchaser.
• Economic Environment: Management notes "no immediate need for cash" and confidence in execution despite global macroeconomic pressures.

Strategic Initiatives:

• Global Expansion: Rolling out the successful U.S. enterprise sales playbook to international markets, increasing investment in international commercial infrastructure.
• Education Partnerships: VCOM (Edward Via College of Osteopathic Medicine) program launched, providing 670 new students/year across four schools with networked devices; graduates taking probes into residency.
• Ecosystem Growth: Signed five new "garden partners" this quarter; DeepEcho app launched for international fetal imaging; continued expansion into Brain-Computer Interface (BCI) with three new partners (Merge Labs, Bridge Neurotech, stealth).
• R&D and Innovation: Developing Apollo platform (convergence of semiconductor ultrasound and physical AI) serving multiple partners; releasing limited batch of wearable prototypes for R&D; developing IQ Station to compete in the cart market.
• Commercialization: Mendera (vascular robotics) has launched its product using Butterfly technology; commercial teams dedicated to specific embedded categories.

Risks and Headwinds to Outlook:

• Embedded Revenue Volatility: Revenue recognized is tied to partner program timing and milestones, not linear quarter-to-quarter.
• Macro & Supply Chain: Potential minor impacts from Middle East conflict, tariffs, and supply chain shortages could affect operations if they escalate.
• Guidance Conservative Nature: Management emphasizes a conservative posture; guidance reflects only signed contracts and visible pipeline, excluding future potential deals that could materially accelerate growth.
• Partner Privacy: Inability to disclose specific partner details or individual customer revenue due to confidentiality agreements, limiting visibility into the embedded pipeline.
• Market Execution: International expansion success relies on successfully transitioning from distributor-led to enterprise-led sales models.

Management Tone on the Future:

• Confidence: Extremely positive; Joe DeVivo states the business is "building a flywheel" and "marching with the inevitability of Moore's law."
• Strategic Shift: Viewing the company as a "platform" rather than just a hardware seller; expecting significant inflection points in 2027 (P5.1 chip) and 2028 (cart launch, home care scaling).
• Discipline: Reaffirmed commitment to capital efficiency, dilution discipline, and ROI-focused spending despite increased R&D (up 17% YoY).
• Outlook: "Very well positioned to close 2026 out strong" and "excited about what's ahead," with a belief that the addressable market is expanding significantly as the technology matures.

Miscellaneous:

• S3 Shelf Registration: Filed a new universal shelf registration statement replacing the expired August 2026 shelf, allowing flexibility to issue up to $150M in securities over three years.
• R&D Investment: R&D spending increased 17% YoY to support Apollo platform and wearable development; expected to continue growing to support embedded pipeline.
• Compass AI Utility: 80% of scans on Compass AI platform currently originate from non-Butterfly hardware, highlighting the software's platform potential and land-and-expand strategy.